The technology, which involves inserting unnatural amino acids (UAAs) at any site within a protein or antibody at commercial scale, has rapidly evolved in the last year, according to James Italia, the company's vice president of commercial development. The platform has recently been validated with data and optimized to allow high throughput for the company's internal efforts, as well as expanded capacity to undertake new pharmaceutical partnerships and co-development initiatives.

The company retains the exclusive rights to use its technology platform for therapeutic development and production.

BrickBio believes it can revolutionize the field of protein therapeutics and antibody drug conjugates using its diverse toolbox of attachment handles (UAAs) to expedite new therapeutics to the clinic, repurpose existing therapeutics, and rescue failed biologics.

Orpheris launches phase II trial for COVID-19 immunotherapy
Orpheris said that the first patients have been enrolled in a phase II trial to assess its OP-101 compound for treating hospitalized adults with severe...

Synaffix, ADC Therapeutics collaborate on antibody drug conjugates
Synaffix and ADC Therapeutics have expanded an existing collaboration to explore additional applications of Synaffix's site-specific conjugation technologies.

DNA 'origami' informs coronavirus vaccine design
Strategically folded DNA arranged to mimic viral antigens -- known as DNA "origami" -- may produce strong immune responses, according to a June 29 report...